COMPARE · Reviewed August 3, 2026
ELV vs PGNY
Verdict: Side-by-side breakdown using the Bull Rankings model. ELV scored 63.9, PGNY scored 63.3 — ELV leads.
Compare another set
Different reporting periods. ELV's fundamentals are as of June 2026, but PGNY's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
ELV
Elevance Health, Inc.
63.9
$379.53 · $82.3B
fundamentals as of
Score gap
0.6
ELV leads
PGNY
Progyny, Inc.
63.3
$31.55 · $2.5B
fundamentals as of
The model, pillar by pillar (0–100 each)
ELV
stronger →← stronger
PGNY
55
Qualityreturns · margins · balance sheet
82
86
Growthrevenue & earnings expansion
72
55
Valuevaluation vs sector peers
43
ELV is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ELV
PGNY
$6.3bB+
FCF
$184mC
+12.6%B+
Rev
+6.6%C+
0.69C+
D/E
0.06A-
16.8xA-
P/E
41.0xC
1.33B
PEG
3.94D
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ELV
PGNY
41% below
Price vs fair valuelower is cheaper
20% below
~-6%/yr
Growth the price implies10-yr FCF · lower = less priced in
~1%/yr
+57%
1-yr DCF upside
+15%
+70%
5-yr DCF upside
+25%
+92%
10-yr DCF upside
+40%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ELV
Why this score
- Buying back stock
PGNY
Why this score
- Buying back stock
- Durable high returns
The companies
ELVElevance Health, Inc.
Why now
Healthcare Plans · market cap $82.3b. 13% off the 52-week high of $436.24. Revenue growing +13%, comfortably above the S&P median. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $449.10 (implying +18% upside).
Moat
ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 127% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $82.3b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Net margin 2.5% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
PGNYProgyny, Inc.
Why now
Healthcare Plans · market cap $2.5b. 5% off the 52-week high of $33.06. 11 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $34.00 (implying +8% upside).
Moat
ROE 15% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.